KalVista Pharmaceuticals Inc.
KALV | NASDAQ
$27
$0 (0.00%)
Jun 10, 2026, 4:00 PM ET · Market open
Fiscal Year Period Ending | FY 2026 Dec 30, 2025 | FY 2025 Apr 29, 2025 | FY 2024 Apr 29, 2024 | FY 2023 Apr 29, 2023 | FY 2022 Apr 29, 2022 | FY 2021 Apr 29, 2021 |
|---|---|---|---|---|---|---|
PE Ratio | -5 | -3.73 | -3.30 | -2.66 | -3.78 | -10.31 |
PEG Ratio | 0.40 | -0.51 | -1 | 2.98 | -0.09 | -0.25 |
PS Ratio | 11.17 | n/a | n/a | n/a | n/a | n/a |
PB Ratio | -303.23 | 7.17 | 2.02 | 1.54 | 1.68 | 1.85 |
P/FCF Ratio | -9.87 | -4.46 | -4.66 | -3.24 | -3.94 | -15.76 |
P/OCF Ratio | -10.07 | -4.47 | -4.68 | -3.29 | -3.99 | -15.80 |
OCF/S Ratio | -110.87 | n/a | n/a | n/a | n/a | n/a |
Debt / Equity Ratio | -55.91 | 0.07 | 0.04 | 0.05 | 0.04 | 0.02 |
Quick Ratio | 5.52 | 5.35 | 9.90 | 11.46 | 16.73 | 27.04 |
Current Ratio | 5.58 | 5.35 | 9.90 | 11.46 | 16.73 | 27.04 |
Asset Turnover | 0.22 | n/a | n/a | n/a | n/a | n/a |
Interest Coverage | -8.88 | -32.50 | n/a | n/a | n/a | n/a |
Return on Equity | 6.06K% | -192.31% | -61.30% | -57.70% | -44.49% | -17.98% |
Return on Assets | -48.99% | -73.15% | -53.80% | -50.71% | -40.39% | -17% |
Return on Invested Capital | -58.89% | -90.57% | -61.55% | -65.50% | -49.99% | -22.02% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 91.75% | n/a | n/a | n/a | n/a | n/a |
Net Profit Margin | -223.16% | n/a | n/a | n/a | n/a | n/a |
Pretax Profit Margin | -232.85% | n/a | n/a | n/a | n/a | n/a |
Operating Profit Margin | -233.42% | n/a | n/a | n/a | n/a | n/a |
FCF Margin | -113.19% | n/a | n/a | n/a | n/a | n/a |
EBITDA Margin | -231.45% | n/a | n/a | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove KALV